Effects of all-trans-retinoic acid incorporated into low-density lipoprotein on invasive properties of multidrug-resistant MCF-7 spheroids.
Cultured cells grown as spheroids provide an in vitro model that is closer to an in vivo tumour than conventional monolayer techniques. Previous work from our laboratory has demonstrated that spheroids formed from multidrug-resistant MCF-7 cells exhibit invasive characteristics which were not present in their sensitive counterparts. The treatment of these spheroids by all-trans-retinoic acid (ATRA), a potent inducer of in vitro and in vivo differentiation, decreases their proteolytic activity and ability to invade Matrigel-coated filters. The efficiency of ATRA is enhanced by its incorporation into low-density lipoprotein (LDL) (LDL-ATRA). Indeed, invasion through a reconstituted basement membrane was reduced by 73% with 10(-6) M ATRA and 3 x 10(-8) M LDL-ATRA. Furthermore, inhibition of invasion was correlated with a decrease in several factors: (1) secreted matrix metalloproteinase-9 and enzymes degrading type IV collagen and Matrigel films, and (2) tissue plasminogen activator. The results observed were found with a concentration of LDL-ATRA 30 times lower than that of ATRA. This could be due to the protective effect of LDL and to a better targeting of cancer cells through their LDL receptors. LDL-ATRA may therefore represent a new and potent inhibitor of invasion that could be developed for clinical trials.
Affoué
M
M
IFR53 Biomolécules, EA 2063, UFR Pharmacie, Reims, France.
Akeli
M G
MG
Gueddari
N
N
Jardillier
J C
JC
Madoulet
C
C
D000970:Antineoplastic Agents / Q000633:toxicity*; D001943:Breast Neoplasms / Q000473:pathology*; D018929:Cell Culture Techniques / Q000379:methods; D002455:Cell Division / Q000187:drug effects; D003094:Collagen; D017364:Collagenases / Q000032:analysis; D017077:Culture Media, Conditioned; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity; D004338:Drug Combinations; D018432:Drug Resistance, Multiple; D005260:Female; D006801:Humans; D007797:Laminin; D008077:Lipoproteins, LDL; D020781:Matrix Metalloproteinase 1 / Q000032:analysis; D009361:Neoplasm Invasiveness / Q000517:prevention & control*; D011509:Proteoglycans; D010959:Tissue Plasminogen Activator / Q000032:analysis; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D017077:Culture Media, Conditioned; D004338:Drug Combinations; D007797:Laminin; D008077:Lipoproteins, LDL; D011509:Proteoglycans; C059485:matrigel; D014212:Tretinoin; D004317:Doxorubicin; D003094:Collagen; D010959:Tissue Plasminogen Activator; D017364:Collagenases; D020781:Matrix Metalloproteinase 1